Search Results
Pirtobrutinib
Pirtobrutinib is indicated for the treatment of
What’s Next in Blood Cancer: Looking Ahead to 2023
The most important blood cancer scientific meeting, the American Society of Hematology (ASH), is held every December.
Helping Blood Cancer Patients and Caregivers Navigate the Financial Impact of COVID-19
The coronavirus (COVID-19) pandemic has been a challenging time for us all. It is especially so for cancer patients and survivors, who are at greater risk of getting sicker if they become infected with the virus because they might be immunocompromised.
#ASH18: Update on Immunotherapy
Immunotherapy – harnessing the body’s immune system to fight disease – is rapidly becoming a mainstay of cancer treatment. The increasing interest in this field was clear at yesterday’s standing-room only symposium hosted by The Leukemia & Lymphoma Society in advance of the 60th ASH (American Society of Hematology) Meeting which officially kicks off today here in San Diego. Over the next few days more than 30,000 researchers and others connected to the blood cancers and other blood malignancies will gather to hear the latest data from clinical trials.
Defining and Redefining a Blood Cancer Diagnosis
Science historian June Goodfield wrote, “Cancer begins and ends with people.”
This Blood Cancer Awareness Month, it’s important to know that The Leukemia & Lymphoma Society (LLS) is on a mission to cure blood cancers and improve quality of life for the nearly 1.7 million people in the U.S. living with or in remission from blood cancer.
LLS is all about people—an organization full of people who are united in the urgent effort to help every person impacted by blood cancer.
Cyclophosphamide
Cyclophosphamide is FDA approved to treat several types of cancer, including people who have Hodgkin lymphoma, non-Hodgkin lymphoma, acute and chronic lymphocytic leukemia, acute and chronic myeloid leukemia, myeloma, and mycosis fungoides. Cyclophosphamide is usually used in combination with other drugs.
Cyclophosphamide may cause a temporary loss of hair in some people. After treatment has ended, normal hair growth should return, although the new hair may be a slightly different color or texture.
Researchers Share Key Career Advice with LLS College Club Members
I recently had the privilege of moderating an LLS on Campus Researcher Panel attended by LLS college club members from nearly 30 universities across the country. These clubs bring together students interested in pursuing health-related careers and provide opportunities to hear from scientists working to better understand and treat blood cancers.
Dacarbazine
Dacarbazine is used to treat people who have Hodgkin lymphoma as a second-line therapy when used in combination with other agents and is also used as initial therapy for some patients with Hodgkin lymphoma. It may cause a temporary loss of hair in some people. After treatment with dacarbazine has ended, normal hair growth should return.
Selinexor
Selinexor is FDA approved
Characterization and Targeting of Tumor-Associated Monocytes/ Macrophages that Limit the Efficacy of PD-1 Blockade in Lymphoma
Inhibition of the PD-1 exhaustion pathway enables the immune system to attack cancers. PD-1 blockade is now a standard treatment for relapsed classic Hodgkin Lymphoma (cHL) and a component of experimental frontline therapy. In patients with cHL, a newly identified population of monocytes/macrophages limits the efficacy of PD-1 blockade. We will characterize and target these tumor-programmed monocytes/macrophages for therapeutic benefit in patients with cHL and other lymphoid malignancies.MLB All-Star Player Designs Caps to Benefit LLS
The Leukemia & Lymphoma Society (LLS) hit a homerun when the Washington Nationals outfielder, Bryce Harper announced LLS will be a beneficiary of his limited edition, custom-designed baseball caps. Known for extraordinary talents in the outfield, Bryce’s talent as a hat designer is now getting recognition: He helped design the New Era caps which went on sale Wednesday, August 24.
Ibritumomab tiuxetan
Ibritumomab tiuxetan is FDA approved to treat people who have relapsed or refractory, low-grade or follicular non-Hodgkin lymphoma (NHL), including patients with follicular NHL that did not respond to therapy with rituximab. It is also FDA approved to treat patients with previously untreated follicular NHL who achieve a partial or complete response to first-line chemotherapy. This drug is a monoclonal antibody with an attached radioisotope to deliver radiation therapy to the lymphoma cells.
Beyond Blankets: Subaru Loves to Care brings comfort and warmth
Blood cancer treatment can be a scary and confusing time. And blood cancer patients want to feel like they’re not alone.
That’s why The Leukemia & Lymphoma Society (LLS) and Subaru are partnering to bring warmth and comfort to blood cancer patients through warm blankets, patient care kits, and handwritten notes of encouragement.
Targeting AML
Not for lack of trying, we’ve seen very little progress over the past 40 years in treating acute myeloid leukemia (AML), an aggressive and deadly blood cancer. But we’re finally starting to see the needle move and The Leukemia & Lymphoma Society (LLS) is playing a leading role in going on the offensive against the disease.